Treats serious bacterial infections caused by susceptible strains of the designated…. ANDA 209621, held by Gland. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 209621 (Tobramycin Sulfate), held by Gland, was first approved by FDA on Feb 11, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Tobramycin injection is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase- and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2021 | Original application | Approved | None posted |
| Tobramycin SulfateEQ 10MG BASE/ML · injectable;injection | Tobramycin Sulfate | Rx |
| Tobramycin SulfateEQ 40MG BASE/ML · injectable;injection | Tobramycin Sulfate | Rx |
| Feb 10, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 11, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters